These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 3027608)

  • 1. Pediatric central nervous system tumors: a cell kinetic study with bromodeoxyuridine.
    Murovic JA; Nagashima T; Hoshino T; Edwards MS; Davis RL
    Neurosurgery; 1986 Dec; 19(6):900-4. PubMed ID: 3027608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A cell kinetic study of human central nervous system tumors with 5-bromodeoxyuridine (BrdU)].
    Nagashima T; Hoshino T
    No To Shinkei; 1985 Dec; 37(12):1195-201. PubMed ID: 3912000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In situ cell kinetics studies on human neuroectodermal tumors with bromodeoxyuridine labeling.
    Hoshino T; Nagashima T; Murovic JA; Wilson CB; Edwards MS; Gutin PH; Davis RL; DeArmond SJ
    J Neurosurg; 1986 Mar; 64(3):453-9. PubMed ID: 3950723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variability in the proliferative potential of human gliomas.
    Hoshino T; Nagashima T; Cho KG; Davis RL; Donegan J; Slusarz M; Wilson CB
    J Neurooncol; 1989 Jul; 7(2):137-43. PubMed ID: 2550593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A correlative study of gliomas using in vivo bromodeoxyuridine labeling index and computer-aided malignancy grading.
    Sharma S; Karak AK; Singh R; Mehta VS; Sarkar C; Schmitt HP
    Pathol Oncol Res; 1999; 5(2):134-41. PubMed ID: 10393366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proliferating cell nuclear antigen (PCNA) immunostaining as an alternative to bromodeoxyuridine (BrdU) immunostaining for brain tumours in paraffin embedded sections.
    Sasaki A; Naganuma H; Kimura R; Isoe S; Nakano S; Nukui H; Suzuki K; Kawaoi A
    Acta Neurochir (Wien); 1992; 117(3-4):178-81. PubMed ID: 1357920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. S-phase fraction of human brain tumors in situ measured by uptake of bromodeoxyuridine.
    Hoshino T; Nagashima T; Cho KG; Murovic JA; Hodes JE; Wilson CB; Edwards MS; Pitts LH
    Int J Cancer; 1986 Sep; 38(3):369-74. PubMed ID: 3527993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proliferative potential of vascular components in human glioblastoma multiforme.
    Nagashima T; Hoshino T; Cho KG
    Acta Neuropathol; 1987; 73(3):301-5. PubMed ID: 3039783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proliferative potential and outcome in pediatric astrocytic tumors.
    Prados MD; Krouwer HG; Edwards MS; Cogen PH; Davis RL; Hoshino T
    J Neurooncol; 1992 Jul; 13(3):277-82. PubMed ID: 1325544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proliferative characteristics of juvenile pilocytic astrocytomas determined by bromodeoxyuridine labeling.
    Ito S; Hoshino T; Shibuya M; Prados MD; Edwards MS; Davis RL
    Neurosurgery; 1992 Sep; 31(3):413-8; discussion 419. PubMed ID: 1407423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MIB-1 labeling index in nonpilocytic astrocytoma of childhood: a study of 101 cases.
    Ho DM; Wong TT; Hsu CY; Ting LT; Chiang H
    Cancer; 1998 Jun; 82(12):2459-66. PubMed ID: 9635540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immunohistochemical study of S-phase cells in human gliomas].
    Ibayashi N; Hirakawa K; Suzuki K; Nakamura K; Houri T
    No To Shinkei; 1988 Aug; 40(8):763-9. PubMed ID: 2460117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Morphological appearance, growth kinetics and glial fibrillary acidic protein (GFAP) expression in primary in vitro explant culture of astrocytic neoplasms.
    Kharbanda K; Sarkar C; Dinda AK; Karak AK; Mathur M; Roy S
    Acta Oncol; 1993; 32(3):301-6. PubMed ID: 8391834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic implications of the bromodeoxyuridine labeling index of human gliomas.
    Hoshino T; Prados M; Wilson CB; Cho KG; Lee KS; Davis RL
    J Neurosurg; 1989 Sep; 71(3):335-41. PubMed ID: 2549222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of the proliferative potential of intracranial gliomas measured by bromodeoxyuridine labeling.
    Hoshino T; Ahn D; Prados MD; Lamborn K; Wilson CB
    Int J Cancer; 1993 Feb; 53(4):550-5. PubMed ID: 8382191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histological grading and bromodeoxyuridine labeling index of astrocytomas. Comparative study in a series of 60 cases.
    Labrousse F; Daumas-Duport C; Batorski L; Hoshino T
    J Neurosurg; 1991 Aug; 75(2):202-5. PubMed ID: 1649271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes of the bromodeoxyuridine labeling index of astrocytic tumors between primary and recurrent lesions.
    Tamura M; Ono N; Zama A; Kurihara H
    Noshuyo Byori; 1994; 11(2):173-6. PubMed ID: 7894621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The proliferative potential of human ependymomas measured by in situ bromodeoxyuridine labeling.
    Nagashima T; Hoshino T; Cho KG; Edwards MS; Hudgins RJ; Davis RL
    Cancer; 1988 Jun; 61(12):2433-8. PubMed ID: 3284636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proliferative activity of meningiomas as evaluated by bromodeoxyuridine uptake examination.
    Fukui M; Iwaki T; Sawa H; Inoue T; Takeshita I; Kitamura K
    Acta Neurochir (Wien); 1986; 81(3-4):135-41. PubMed ID: 3529838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Factors affecting the prognosis of brain tumors].
    Yoshimine T; Hayakawa T; Mogami H
    Gan To Kagaku Ryoho; 1988 Jul; 15(7):2022-7. PubMed ID: 2840033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.